This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Health product recall

ADVIA CENTAUR SYSTEMS (2015-12-30)

Starting date:
December 30, 2015
Posting date:
January 22, 2016
Type of communication:
Medical Device Recall
Subcategory:
Medical Device
Hazard classification:
Type III
Source of recall:
Health Canada
Issue:
Medical Devices
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-56778

Affected Products 

  1. ADVIA CENTAUR CP SYSTEM - PROSTATE-SPECIFIC ANTIGEN
  2. ADVIA CENTAUR SYSTEM - PROSTATE-SPECIFIC ANTIGEN

Reason

Not meeting the current High-Dose Hook Effect expectation in the Instructions For Use (IFU). The ADVIA Centaur systems PSA assay range is 0.01-100 ng/mL (μg/L). The ADVIA Centaur Systems PSA IFU states that patient samples with high total PSA levels can cause a paradoxical decrease in the Relative Light Units (RLUs) (high-dose hook effect). In this assay, patient samples with total PSA levels as high as 10,000 ng/mL (μg /L) will assay greater than 100 ng/mL (μg/L).

Affected products

A. ADVIA CENTAUR CP SYSTEM - PROSTATE-SPECIFIC ANTIGEN

Lot or serial number

ending in 263 and above

Model or catalog number

118156

Companies
Manufacturer
Siemens Healthcare Diagnostics Inc.
511 Benedict Ave
Tarrytown
10591
New York
UNITED STATES

B. ADVIA CENTAUR SYSTEM - PROSTATE-SPECIFIC ANTIGEN

Lot or serial number

ending in 263 and above

Model or catalog number

118157

Companies
Manufacturer
Siemens Healthcare Diagnostics Inc.
511 Benedict Ave
Tarrytown
10591
New York
UNITED STATES